AVEO Oncology (NASDAQ:AVEO) today announced that poster
presentations for three clinical studies will be presented at the
upcoming 2017 American Society of Clinical Oncology (ASCO) Annual
Meeting, held June 2-6, 2017.
Among these is a Trials in Progress presentation highlighting
the ongoing Phase 3, randomized, controlled, multi-center,
open-label TIVO-3 study comparing tivozanib, the Company’s potent,
selective, long half-life inhibitor of all three vascular
endothelial growth factor (VEGF) receptors, to sorafenib in
subjects with refractory advanced renal cell carcinoma. The
remaining two presentations will highlight ficlatuzumab, the
Company’s potent hepatocyte growth factor (HGF) inhibitory antibody
that binds to the HGF ligand with high affinity and specificity to
inhibit HGF/c-Met biological activities, in two
investigator-sponsored studies, one in head and neck squamous cell
carcinoma and the other in acute myeloid leukemia.
Tivozanib is partnered for oncologic indications with EUSA
Pharma under an exclusive license agreement covering territories
outside of North America and Asia, including Europe, South America
and South Africa. AVEO and Biodesix, Inc. have a worldwide
agreement to develop and commercialize ficlatuzumab.
Details for the poster presentations at ASCO 2017:
Title: Tivo-3: A phase 3,
randomized, controlled, multi-center, open-label study to
comparetivozanib hydrochloride to sorafenib in subjects with
refractory advanced renal cell carcinoma (RCC)
Presenter: Brian I. Rini, MD, FACP,
Professor of Medicine, Lerner College of Medicine,Leader, GU
Program, Department of Hematology and Oncology, Cleveland Clinic
Taussig Cancer Institute
Abstract Number: TPS4600
Session: Genitourinary
(Nonprostate) Cancer
Date and Time: Sunday, June 4,
2017, 8:00-11:30 AM CT
Title: Phase I study of the
anti-HGF monoclonal antibody (mAb), ficlatuzumab, and cetuximabin
cetuximab-resistant, recurrent/metastatic (R/M) head and neck
squamous cell carcinoma (HNSCC)
Presenter: Julie E. Bauman, MD,
MPH, Chief, Division of Hematology and Oncology,Associate Director,
Translational Research, University of Arizona Cancer Center
Abstract Number: 6038
Session: Head and Neck Cancer
Date and Time: Monday, June 5,
2017, 1:15-4:45 PM CT
Title: CyFi: A phase I study
exploring the role of cMET pathway inhibition withficlatuzumab (Fi)
combined with high-dose cytarabine (Cy) in patients withhigh risk
relapsed or refractory acute myeloid leukemia (AML)
Presenter: Charalambos (Babis)
Andreadis, MD, Hematologic Malignancies andBlood and Marrow
Transplantation Program, University of California, San
Francisco
Abstract Number: 7040
Session: Hematologic
Malignancies—Leukemia, Myelodysplastic Syndromes, and
Allotransplant
Date and Time: Monday, June 5,
2017, 8:00-11:30 AM CT
About AVEO
AVEO Oncology (AVEO) is a biopharmaceutical company dedicated to
advancing a broad portfolio of targeted therapeutics for oncology
and other areas of unmet medical need. The company is focused on
seeking to develop and commercialize its lead candidate tivozanib,
a potent, selective, long half-life inhibitor of vascular
endothelial growth factor 1, 2 and 3 receptors, in North America as
a treatment for renal cell carcinoma and other cancers. AVEO is
leveraging multiple partnerships aimed at developing and
commercializing tivozanib in non-oncologic indications worldwide
and oncology indications outside of North America, as well as to
progress its pipeline of novel therapeutic candidates in cancer and
cachexia (wasting syndrome). For more information, please visit the
company’s website at www.aveooncology.com.
Cautionary Note Regarding Forward-Looking Statements
This press release contains forward-looking statements of AVEO
that involve substantial risks and uncertainties. All statements,
other than statements of historical fact, contained in this press
release are forward-looking statements. The words “anticipate,”
“believe,” “expect,” “intend,” “may,” “plan,” “potential,” “could,”
“should,” “would,” “seek,” “look forward,” “advance,” “goal,”
“strategy,” or the negative of these terms or other similar
expressions, are intended to identify forward-looking statements,
although not all forward-looking statements contain these
identifying words. These forward-looking statements include, among
others: AVEO’s and its collaborators’ future discovery, development
and commercialization plans and efforts, including without
limitation with respect to tivozanib, ficlatuzumab and AVEO’s other
programs and platforms; and AVEO’s strategy, prospects, plans and
objectives. AVEO has based its expectations and estimates on
assumptions that may prove to be incorrect. As a result, readers
are cautioned not to place undue reliance on these expectations and
estimates. Actual results or events could differ materially from
the plans, intentions and expectations disclosed in the
forward-looking statements that AVEO makes due to a number of
important factors, including risks relating to AVEO’s ability to
enter into and maintain its third party collaboration agreements,
and its ability, and the ability of its licensees and other
partners, to achieve development and commercialization objectives
under these arrangements; AVEO’s ability, and the ability of its
licensees, to demonstrate to the satisfaction of applicable
regulatory agencies the safety, efficacy and clinically meaningful
benefit of AVEO’s product candidates; AVEO’s ability to
successfully enroll and complete clinical trials, including the
TIVO-3 and TiNivo studies; AVEO’s ability to achieve and maintain
compliance with all regulatory requirements applicable to its
product candidates; AVEO’s ability to obtain and maintain adequate
protection for intellectual property rights relating to its product
candidates and technologies; developments, expenses and outcomes
related to AVEO’s ongoing shareholder litigation; AVEO’s ability to
successfully implement its strategic plans; AVEO’s ability to raise
the substantial additional funds required to achieve its goals,
including those goals pertaining to the development and
commercialization of tivozanib; unplanned capital requirements;
adverse general economic and industry conditions; competitive
factors; and those risks discussed in the section titled “Risk
Factors” and “Management’s Discussion and Analysis of Financial
Condition and Results of Operations—Liquidity and Capital
Resources” included in AVEO’s Annual Report on Form 10-K for the
year ended December 31, 2016 and in other filings that AVEO may
make with the SEC in the future. The forward-looking statements in
this press release represent AVEO’s views as of the date of this
press release. AVEO anticipates that subsequent events and
developments may cause its views to change. While AVEO may elect to
update these forward-looking statements at some point in the
future, it specifically disclaims any obligation to do so. You
should, therefore, not rely on these forward-looking statements as
representing AVEO's views as of any date other than the date of
this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170420005909/en/
for AVEOArgot PartnersDavid Pitts,
212-600-1902aveo@argotpartners.com
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Mar 2024 to Apr 2024
AVEO Pharmaceuticals (NASDAQ:AVEO)
Historical Stock Chart
From Apr 2023 to Apr 2024